{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:32:18Z","timestamp":1787027538847,"version":"build-2736575974"},"reference-count":83,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Neurological Research","award":["LX22NPO5107"],"award-info":[{"award-number":["LX22NPO5107"]}]},{"name":"National Institute for Neurological Research","award":["IP No. 111, GIP-22-SL-05-212"],"award-info":[{"award-number":["IP No. 111, GIP-22-SL-05-212"]}]},{"name":"National Institute for Neurological Research","award":["MH CZ\u2014DRO-VFN64165"],"award-info":[{"award-number":["MH CZ\u2014DRO-VFN64165"]}]},{"name":"European Union\u2014Next Generation EU","award":["LX22NPO5107"],"award-info":[{"award-number":["LX22NPO5107"]}]},{"name":"European Union\u2014Next Generation EU","award":["IP No. 111, GIP-22-SL-05-212"],"award-info":[{"award-number":["IP No. 111, GIP-22-SL-05-212"]}]},{"name":"European Union\u2014Next Generation EU","award":["MH CZ\u2014DRO-VFN64165"],"award-info":[{"award-number":["MH CZ\u2014DRO-VFN64165"]}]},{"name":"General University Hospital in Prague","award":["LX22NPO5107"],"award-info":[{"award-number":["LX22NPO5107"]}]},{"name":"General University Hospital in Prague","award":["IP No. 111, GIP-22-SL-05-212"],"award-info":[{"award-number":["IP No. 111, GIP-22-SL-05-212"]}]},{"name":"General University Hospital in Prague","award":["MH CZ\u2014DRO-VFN64165"],"award-info":[{"award-number":["MH CZ\u2014DRO-VFN64165"]}]},{"name":"Charles University","award":["LX22NPO5107"],"award-info":[{"award-number":["LX22NPO5107"]}]},{"name":"Charles University","award":["IP No. 111, GIP-22-SL-05-212"],"award-info":[{"award-number":["IP No. 111, GIP-22-SL-05-212"]}]},{"name":"Charles University","award":["MH CZ\u2014DRO-VFN64165"],"award-info":[{"award-number":["MH CZ\u2014DRO-VFN64165"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Multiple system atrophy (MSA) is generally a sporadic neurodegenerative disease which ranks among atypical Parkinson\u2019s syndromes. The main clinical manifestation is a combination of autonomic dysfunction and parkinsonism and\/or cerebellar disability. The disease may resemble other Parkinsonian syndromes, such as Parkinson\u2019s disease (PD) or progressive supranuclear palsy (PSP), from which MSA could be hardly distinguishable during the first years of progression. Due to the lack of a reliable and easily accessible biomarker, the diagnosis is still based primarily on the clinical picture. Recently, reduced levels of coenzyme Q10 (CoQ10) were described in MSA in various tissues, including the central nervous system. The aim of our study was to verify whether the level of CoQ10 in plasma and lymphocytes could serve as an easily available diagnostic biomarker of MSA. The study reported significantly lower levels of CoQ10 in the lymphocytes of patients with MSA compared to patients with PD and controls. The reduction in CoQ10 levels in lymphocytes correlated with the increasing degree of clinical involvement of patients with MSA. CoQ10 levels in lymphocytes seem to be a potential biomarker of disease progression.<\/jats:p>","DOI":"10.3390\/antiox12122104","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T09:15:33Z","timestamp":1702372533000},"page":"2104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-2422","authenticated-orcid":false,"given":"Tereza","family":"Barto\u0161ov\u00e1","sequence":"first","affiliation":[{"name":"Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Klemp\u00ed\u0159","sequence":"additional","affiliation":[{"name":"Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-225X","authenticated-orcid":false,"given":"Hana","family":"Hans\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"Laboratory for Study of Mitochondrial Disorders, Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(94)00395-5","article-title":"Identification of two distinct synucleins from human brain","volume":"345","author":"Jakes","year":"1994","journal-title":"FEBS Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0896-6273(01)00462-7","article-title":"\u03b2-Synuclein inhibits \u03b1-synuclein aggregation: A possible role as an anti-parkinsonian factor","volume":"32","author":"Hashimoto","year":"2001","journal-title":"Neuron"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnen\/59.7.592","article-title":"Novel Immunolocalization of \u03b1-Synuclein in Human Muscle of Inclusion-Body Myositis, Regenerating and Necrotic Muscle Fibers, and at Neuromuscular Junctions","volume":"59","author":"Askanas","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10059-000-0065-x","article-title":"Expression Patterns of \u03b1-Synuclein in Human Hematopoietic Cells and in Drosophila at Different Developmental Stages","volume":"10","author":"Shin","year":"2000","journal-title":"Mol. Cells"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1385\/JMN:22:3:199","article-title":"\u03b1-synuclein is expressed in different tissues during human fetal development","volume":"22","author":"Baltic","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(02)00297-5","article-title":"Expression of \u03b1-synuclein, the precursor of non-amyloid \u03b2 component of Alzheimer\u2019s disease amyloid, in human cerebral blood vessels","volume":"326","author":"Tamo","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0161-813X(02)00066-9","article-title":"Conformational behavior of human \u03b1-synuclein is modulated by familial Parkinson\u2019s disease point mutations A30P and A53T","volume":"23","author":"Li","year":"2002","journal-title":"Neurotoxicology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.parkreldis.2003.11.005","article-title":"\u03b1-synuclein, Parkinson\u2019s disease, and Alzheimer\u2019s disease","volume":"10","author":"Kim","year":"2004","journal-title":"Park. Relat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Fukushima","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12305","DOI":"10.1523\/JNEUROSCI.3088-08.2008","article-title":"Optical reporters for the conformation of \u03b1-synuclein reveal a specific interaction with mitochondria","volume":"28","author":"Nakamura","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-019-0730-6","article-title":"Understanding the pathogenesis of multiple system atrophy: State of the art and future perspectives","volume":"7","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11910-017-0751-0","article-title":"Multiple System Atrophy\u2014State of the Art","volume":"17","author":"Laurens","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/brain\/awx044","article-title":"Insulin resistance and exendin-4 treatment for multiple system atrophy","volume":"140","author":"Bassil","year":"2017","journal-title":"Brain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1017\/cjn.2016.261","article-title":"Oxidative Stress and Environmental Exposures are Associated with Multiple System Atrophy in Chinese Patients","volume":"43","author":"Zhou","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1038\/s41598-019-42902-7","article-title":"Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson\u2019s disease","volume":"9","author":"Foti","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/mds.870120323","article-title":"Mitochondrial respiratory chain function in multiple system atrophy","volume":"12","author":"Gu","year":"1997","journal-title":"Mov. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/WNR.0b013e3282f03db4","article-title":"Localization of \u03b1-synuclein to mitochondria within midbrain of mice","volume":"18","author":"Li","year":"2007","journal-title":"Neuroreport"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2009.02.056","article-title":"\u03b1-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity","volume":"454","author":"Liu","year":"2009","journal-title":"Neurosci. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1471-4159.1998.71010338.x","article-title":"Expression pattern of synucleins (non-A\u03b2 component of Alzheimer\u2019s disease amyloid precursor protein\/\u03b1-synuclein) during murine brain development","volume":"71","author":"Hsu","year":"1998","journal-title":"J. Neurochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0304-3940(02)00016-2","article-title":"Human \u03b1-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine","volume":"320","author":"Junn","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbadis.2009.08.013","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"1802","author":"Winklhofer","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13731","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"139","author":"Bose","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.expneurol.2009.03.006","article-title":"Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson\u2019s disease","volume":"218","year":"2009","journal-title":"Exp. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/emboj.2012.170","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease: Molecular mechanisms and pathophysiological consequences","volume":"31","author":"Exner","year":"2012","journal-title":"EMBO J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","article-title":"MPTP toxicity: Implications for research in Parkinson\u2019s disease","volume":"11","author":"Kopin","year":"1988","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cuenca-Bermejo, L., Pizzichini, E., Gon\u00e7alves, V.C., Guill\u00e9n-D\u00edaz, M., Aguilar-Mo\u00f1ino, E., S\u00e1nchez-Rodrigo, C., Gonz\u00e1lez-Cuello, A.-M., Fern\u00e1ndez-Villalba, E., and Herrero, M.T. (2021). A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094341"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/mds.21992","article-title":"Red flags for multiple system atrophy","volume":"23","author":"Geser","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autneu.2017.10.007","article-title":"Diagnosis of multiple system atrophy","volume":"211","author":"Palma","year":"2018","journal-title":"Auton. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/mdc3.12404","article-title":"Role of Magnetic Resonance Imaging in the Diagnosis of Multiple System Atrophy","volume":"4","author":"Kim","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2017.10.010","article-title":"Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy","volume":"46","author":"Compta","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/jamaneurol.2016.4133","article-title":"Plasma Coenzyme Q10 Levels and Multiple System Atrophy-Reply","volume":"73","author":"Mitsui","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Schottlaender, L.V., Bettencourt, C., Kiely, A.P., Chalasani, A., Neergheen, V., Holton, J.L., Hargreaves, I., and Houlden, H. (2016). Coenzyme Q10 Levels Are Decreased in the Cerebellum of Multiple-System Atrophy Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149557"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-2275(20)37636-7","article-title":"Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress","volume":"37","author":"Lagendijk","year":"1996","journal-title":"J. Lipid Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10286-014-0267-5","article-title":"Multiple system atrophy: The application of genetics in understanding etiology","volume":"25","author":"Federoff","year":"2015","journal-title":"Clin. Auton. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Payan, C.A., Viallet, F., Landwehrmeyer, B.G., Bonnet, A.-M., Borg, M., Durif, F., Lacomblez, L., Bloch, F., Verny, M., and Fermanian, J. (2011). Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: Validation of the NNIPPS\u2014Parkinson Plus Scale. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022293"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/mds.20255","article-title":"Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)","volume":"19","author":"Wenning","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1038\/s41598-018-27985-y","article-title":"Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington\u2019s disease patients","volume":"8","author":"Askeland","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Krizova, J., Hulkova, M., Capek, V., Mlejnek, P., Silhavy, J., Tesarova, M., Zeman, J., and Hansikova, H. (2021). Microarray and qPCR Analysis of Mitochondrial Metabolism Activation during Prenatal and Early Postnatal Development in Rats and Humans with Emphasis on CoQ(10) Biosynthesis. Biology, 10.","DOI":"10.3390\/biology10050418"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0076-6879(69)13005-0","article-title":"[1] Citrate synthase. [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]","volume":"13","author":"Srere","year":"1969","journal-title":"Methods Enzymol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/abio.2002.5653","article-title":"Assay of coenzyme Q(10) in plasma by a single dilution step","volume":"305","author":"Mosca","year":"2002","journal-title":"Anal. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2018.07.017","article-title":"Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy","volume":"57","author":"Du","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson\u2019s disease","volume":"53","author":"Jenner","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Parkinsons Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mantle, D., and Dybring, A. (2020). Bioavailability of Coenzyme Q(10): An Overview of the Absorption Process and Subsequent Metabolism. Antioxidants, 9.","DOI":"10.3390\/antiox9050386"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kasai, T., Tokuda, T., Ohmichi, T., Ishii, R., Tatebe, H., Nakagawa, M., and Mizuno, T. (2016). Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147574"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/jamaneurol.2016.1810","article-title":"Coenzyme Q10 as a Peripheral Biomarker for Multiple System Atrophy","volume":"73","author":"Kuo","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.chemphyslip.2011.04.002","article-title":"Oxysterols as biomarkers in neurodegenerative diseases","volume":"164","author":"Leoni","year":"2011","journal-title":"Chem. Phys. Lipids"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00415-010-5805-z","article-title":"Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis","volume":"258","author":"Dorst","year":"2011","journal-title":"J Neurol"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, E., Grosso, G., Nieves, J.W., Zangh\u00ec, A., Factor-Litvak, P., and Mitsumoto, H. (2021). Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. Nutrients, 13.","DOI":"10.3390\/nu13072273"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12944-020-01284-w","article-title":"A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson\u2019s disease","volume":"19","author":"Fu","year":"2020","journal-title":"Lipids Health Dis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/01.CIR.46.4.709","article-title":"Serum lipids and lipoproteins in men after myocardial infarction compared with representative population sample","volume":"46","author":"Gustafson","year":"1972","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-5793(98)01712-8","article-title":"Determinants of plasma coenzyme Q10 in humans","volume":"443","author":"Kaikkonen","year":"1999","journal-title":"FEBS Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s007020070050","article-title":"Serum levels of coenzyme Q10 in patients with Parkinson\u2019s disease","volume":"107","author":"Molina","year":"2000","journal-title":"J. Neural. Transm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbacli.2014.09.003","article-title":"Noninvasive diagnostics of mitochondrial disorders in isolated lymphocytes with high resolution respirometry","volume":"2","author":"Pecina","year":"2014","journal-title":"BBA Clin."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mito.2019.07.013","article-title":"Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer\u2019s disease and depressive disorder","volume":"48","author":"Wenchich","year":"2019","journal-title":"Mitochondrion"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2174\/1567205013666160314150856","article-title":"Mitochondrial Respiration in the Platelets of Patients with Alzheimer\u2019s Disease","volume":"13","author":"Wenchich","year":"2016","journal-title":"Curr. Alzheimer. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1373\/clinchem.2005.054643","article-title":"Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard","volume":"51","author":"Duncan","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0140-6736(00)02531-9","article-title":"Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency","volume":"356","author":"Appelkvist","year":"2000","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4103\/0028-3886.28112","article-title":"Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson\u2019s disease: Preliminary study","volume":"54","author":"Shinde","year":"2006","journal-title":"Neurol. India"},{"key":"ref_64","first-page":"41","article-title":"Reversal of oxidative stress-induced apoptosis in T and B lymphocytes by Coenzyme Q10 (CoQ10)","volume":"5","author":"Gollapudi","year":"2016","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.bbadis.2018.09.018","article-title":"Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy","volume":"1864","author":"Kleiner","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cccn.2003.12.020","article-title":"Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: Comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults","volume":"342","author":"Niklowitz","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nut.2009.08.008","article-title":"Clinical aspects of coenzyme Q10: An update","volume":"26","author":"Littarru","year":"2010","journal-title":"Nutrition"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"14215","DOI":"10.1038\/s41598-018-32573-1","article-title":"The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy","volume":"8","author":"Nakamoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/nan.12661","article-title":"Signs of early cellular dysfunction in multiple system atrophy","volume":"47","author":"Krismer","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0022-510X(94)90248-8","article-title":"Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson\u2019s disease and multiple system atrophy","volume":"125","author":"Blin","year":"1994","journal-title":"J. Neurol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000046889","article-title":"Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson\u2019s disease","volume":"10","author":"Ebadi","year":"2001","journal-title":"Biol. Signals Recept."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bbabio.2016.03.010","article-title":"Coenzyme Q biosynthesis and its role in the respiratory chain structure","volume":"1857","author":"Navas","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Multiple-System Atrophy Research Collaboration (2013). Mutations in COQ2 in familial and sporadic multiple-system atrophy. N. Engl. J. Med., 369, 233\u2013244.","DOI":"10.1056\/NEJMoa1212115"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.1073\/pnas.1809969115","article-title":"Coding mutations in NUS1 contribute to Parkinson\u2019s disease","volume":"115","author":"Guo","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2051-5960-2-15","article-title":"Lipid dysfunction and pathogenesis of multiple system atrophy","volume":"2","author":"Bleasel","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.parkreldis.2020.10.040","article-title":"Association of mitochondrial genomic background with risk of Multiple System Atrophy","volume":"81","author":"Valentino","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12311-017-0846-9","article-title":"Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 Mutations","volume":"16","author":"Mitsui","year":"2017","journal-title":"Cerebellum"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.amjmed.2017.10.021","article-title":"Coenzyme Q10 Supplementation in Orthostatic Hypotension and Multiple-System Atrophy: A Report on 7 Cases","volume":"131","author":"Rembold","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.parkreldis.2018.01.020","article-title":"Ubiquinone, ubiquinol, 4-hydroxybenzoic acid\u2026 What \u2018coenzyme Q10\u2019 should we care about in multiple system atrophy?","volume":"50","author":"Compta","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.parkreldis.2018.01.019","article-title":"4-Hydroxybenzoic acid for multiple system atrophy?","volume":"50","author":"Distelmaier","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mdc3.12145","article-title":"Current Concepts in the Treatment of Multiple System Atrophy","volume":"2","author":"Flabeau","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1468-1331.2002.00348.x","article-title":"The symptomatic treatment of multiple system atrophy","volume":"9","author":"Colosimo","year":"2002","journal-title":"Eur. J. Neurol."},{"key":"ref_83","first-page":"61","article-title":"The Differential Diagnosis and Treatment of Atypical Parkinsonism","volume":"113","author":"Levin","year":"2016","journal-title":"Dtsch. Arztebl. Int."}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/12\/12\/2104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:29Z","timestamp":1760132249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/12\/12\/2104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":83,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["antiox12122104"],"URL":"https:\/\/doi.org\/10.3390\/antiox12122104","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}